Payment overview · 2025
General Payments
$1,867.68
107 reported records · 22 companies
Healthcare provider profile · identity verified
Nima Amjadi, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · DRIPPING SPRINGS, TX · NPI 1114974011
Verified facts
What the public records show
CMS Open Payments records show Nima Amjadi, M.D. received $1,867.68 in general payments during 2025 across 107 reported records.
Novartis Pharmaceuticals Corporation accounted for 17.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Edarbi, Eliquis, Entresto, Farxiga, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBI as an associated drug or biological on 1140 records involving 805 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Edarbi by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBYCLOR as an associated drug or biological on 283 records involving 215 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Edarbyclor by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 330 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 330 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $333.54 | 17.9% | 23 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $261.72 | 14.0% | 21 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $208.61 | 11.2% | 16 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $143.71 | 7.7% | 12 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $139.38 | 7.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $136.50 | 7.3% | 13 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $123.47 | 6.6% | 1 | 2025 |
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $91.26 | 4.9% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $50.82 | 2.7% | 2 | 2025 |
| Cook Medical LLC | Unresolved — no canonical attribution shown | $50.58 | 2.7% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $43.31 | 2.3% | 2 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $39.68 | 2.1% | 1 | 2025 |
| Imperative Care, Inc | Unresolved — no canonical attribution shown | $37.97 | 2.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $36.97 | 2.0% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $29.83 | 1.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.59 | 1.5% | 1 | 2025 |
| Flowphysix Inc | Unresolved — no canonical attribution shown | $21.47 | 1.1% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $21.41 | 1.1% | 1 | 2025 |
| Siemens Medical Solutions USA, Inc. | Unresolved — no canonical attribution shown | $18.80 | 1.0% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.11 | 1.0% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.52 | 0.9% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $15.43 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,867.68 | 107 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $320.96 | 21 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $233.92 | 20 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $143.71 | 12 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $139.38 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $136.50 | 13 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $127.25 | 9 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $123.47 | 1 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $123.47 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $105.34 | 8 | 2025 |
Source payment records
|
|||||
| EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX Normalized: epi sense guided coagulation system with visitrax |
Device | AtriCure, Inc. | $91.26 | 3 | 2025 |
Source payment records
|
|||||
| ZENITH Normalized: zenith |
Device | Cook Medical LLC | $50.58 | 1 | 2025 |
Source payment records
|
|||||
| EVKEEZA Normalized: evkeeza |
Biological | Regeneron Healthcare Solutions, Inc. | $43.31 | 2 | 2025 |
Source payment records
|
|||||
| PRALUENT Normalized: praluent |
Biological | Regeneron Healthcare Solutions, Inc. | $43.31 | 2 | 2025 |
Source payment records
|
|||||
| Hillrom - Cardiac Ambulatory Monitor Normalized: hillrom cardiac ambulatory monitor |
Device | Baxter Healthcare | $39.68 | 1 | 2025 |
Source payment records
|
|||||
| SYMPHONY CATHETER Normalized: symphony catheter |
Device | Imperative Care, Inc | $37.97 | 1 | 2025 |
Source payment records
|
|||||
| ATRICLIP LAA EXCLUSION SYSTEM Normalized: atriclip laa exclusion system |
Device | AtriCure, Inc. | $35.12 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $29.83 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $27.59 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $26.84 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $23.20 | 1 | 2025 |
Source payment records
|
|||||
| FLOWRUNNER Normalized: flowrunner |
Device | Flowphysix Inc | $21.47 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $21.41 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $21.41 | 1 | 2025 |
Source payment records
|
|||||
| Artis icono floor Normalized: artis icono floor |
Device | Siemens Medical Solutions USA, Inc. | $18.80 | 1 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $18.11 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $17.52 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $13.77 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $12.58 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $8.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| EDARBI edarbi |
2025 | Edarbi | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 330 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 84 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 42 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 74 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBI open payments reported associated product |
CMS Open Payments — General Payments 1140 supporting records · 805 recipient NPIs · example record 1242666830 |
Edarbi · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBYCLOR open payments reported associated product |
CMS Open Payments — General Payments 283 supporting records · 215 recipient NPIs · example record 1242666846 |
Edarbyclor · 2024 Exact normalized brand match · 1 Part D row |
51 | 16 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
330 | 91 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
42 | 11 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
84 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
74 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
330 | 91 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1014 | 341 |
| Nebivolol Hcl | Nebivolol Hcl | 573 | 188 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 371 | 115 |
| Metoprolol Succinate | Metoprolol Succinate | 350 | 119 |
| Eliquis | Apixaban | 330 | 91 |
| Atorvastatin Calcium | Atorvastatin Calcium | 320 | 98 |
| Xarelto | Rivaroxaban | 244 | 65 |
| Furosemide | Furosemide | 211 | 100 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 174 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 164 | 51 |
| Nifedipine Er | Nifedipine | 155 | 61 |
| Clopidogrel | Clopidogrel Bisulfate | 142 | 65 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 138 | 40 |
| Carvedilol | Carvedilol | 129 | 42 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 123 | 39 |
| Repatha Sureclick | Evolocumab | 107 | 33 |
| Flecainide Acetate | Flecainide Acetate | 99 | 33 |
| Entresto | Sacubitril/Valsartan | 84 | 20 |
| Potassium Chloride | Potassium Chloride | 83 | 35 |
| Ezetimibe | Ezetimibe | 78 | 36 |
| Ozempic | Semaglutide | 74 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 60 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 58 | 16 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 51 | 16 |
| Valsartan | Valsartan | 50 | 18 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 49 | 15 |
| Amiodarone Hcl | Amiodarone Hcl | 46 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 45 | 11 |
| Torsemide | Torsemide | 43 | 20 |
| Mounjaro | Tirzepatide | 42 | 11 |
| Losartan Potassium | Losartan Potassium | 41 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 40 | 13 |
| Lisinopril | Lisinopril | 40 | 18 |
| Farxiga | Dapagliflozin Propanediol | 35 | suppressed |
| Omeprazole | Omeprazole | 32 | 11 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 28 | suppressed |
| Vascepa | Icosapent Ethyl | 28 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 27 | suppressed |
| Ranolazine Er | Ranolazine | 26 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 23 | suppressed |
| Brilinta | Ticagrelor | 21 | suppressed |
| Edarbi | Azilsartan Medoxomil | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | 11 |
| Irbesartan | Irbesartan | 17 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,867.68 · 107 records | Novartis Pharmaceuticals Corporation | ATRICLIP LAA EXCLUSION SYSTEM, Artis icono floor, CAMZYOS, EDARBI, ELIQUIS, ENDOCROSS Device, ENTRESTO, EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX, EVKEEZA, FARXIGA, FLOWRUNNER, FUROSCIX, Flexitouch Plus, Hillrom - Cardiac Ambulatory Monitor, JARDIANCE, LEQVIO, LOKELMA, MOUNJARO, NEXLETOL, Nimbl, Ozempic, PRALUENT, REPATHA, SYMPHONY CATHETER, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, Torus Stent Graft System, VYNDAQEL, WATCHMAN Access System, ZENITH, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Edarbi play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error